At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
Ciprofloxacin (Cipro, BAYQ3939) +1 moredrug
Likely dose
Ciprofloxacin (Cipro, BAYQ3939) 32,5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis
In Brief
A Phase 2 clinical trial evaluating Ciprofloxacin (Cipro, BAYQ3939) and Placebo for Bronchiectasis. Completed, enrolled 124 participants across 47 sites in 6 countries.
Detailed Summary
The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiectasis
CountriesAustralia, Germany, Spain, Sweden, United Kingdom, United States
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJul 2009
Primary CompletionSep 2010
TodayJul 2026
First PostedJul 2, 2009
Enrollment StartJun 1, 2009
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17 years ago
Interventions
Ciprofloxacin (Cipro, BAYQ3939)drug
Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
Placebodrug
Inhalation of matching placebo twice a day